Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 22INDUSTRY 15NETWORK 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 10Mesothelioma, Malignant 6Solitary Fibrous Tumor, Pleural 2Adenocarcinoma of Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Pathologic Complete Response 1Mesothelioma 1

Interventions

LMB-100 4Cyclophosphamide 3fludarabine 2Plicamycin 2Cisplatin 2talazoparib 1pembrolizumab 1olaparib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1amatuximab 1alvocidib 1aldesleukin 1Surgical Procedures, Operative 1Pentostatin 1Pemetrexed 1Paclitaxel 1Magnetic Resonance Imaging 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Famotidine 1FANG vaccine 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Dexamethasone 1Depsipeptides 1Cytoreduction Surgical Procedures 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mesothelioma × Pemetrexed × Clear all
NCT01445392 2018-08-03

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
24 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡